Volume 93, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Nifurtimox (NFX) is one of the approved drugs used to treat Chagas disease. Safety profile studies and models on risk factors for treatment interruption in adults are scarce in Latin America. This study evaluated retrospectively the medical records of adult Chagas disease patients treated with NFX between 2007 and 2012 in Bogotá, Colombia. An accelerated failure time model was used, and associations were expressed as time ratio (TR). In total, 76 adult patients with NFX were included: 60 (79.0%) completed 60 days of treatment, 61 (80.3%) presented adverse drug reactions (ADRs), and 16 (21.0%) required treatment interruption. The predominant symptoms were epigastric pain (23.7%), nauseas (18.4%), sleep disturbances (18.4%), loss of appetite (17.1%), and temporary loss of memory (15.2%). ADRs were classified as mild (64.5%), moderate (30.4%), and severe (5.1%). Time of treatment was significantly longer when presenting ≤ 3 ADRs (TR: 1.78; 95% CI: 1.04–3.03), presence of non-severe ADRs (TR: 6.52; 95% CI: 3.24–13.1), doses of NFX ≤ 8 mg/kg/day (TR: 1.78; 95% CI: 0.90–3.49), and age < 48 years (TR: 1.57; 95% CI: 0.90–2.74). Treatment with NFX in adults caused a high frequency of ADRs, but most of the cases were mild and did not require treatment interruption. Severity and number of ADRs were the main predictors for treatment interruption.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. WHO, 2010. Chagas Disease: Control and Elimination. World Health Assembly Report. Geneva, Switzerland: World Health Organization, 14. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_17-en.pdf. Accessed February 25, 2014. [Google Scholar]
  2. WHO, 2010. First WHO Report on Neglected Tropical Diseases: Working to Overcome the Global Impact of Neglected Tropical Diseases. Geneva, Switzerland: World Health Organization, 1172. Available at: http://www.who.int/neglected_diseases/2010report/en/. Accessed February 25, 2014. [Google Scholar]
  3. WHO, 2015. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 90: 3343. [Google Scholar]
  4. Rassi A, Jr Rassi A, Little WC, , 2000. Chagas' heart disease. Clin Cardiol 23: 883889.[Crossref] [Google Scholar]
  5. Rocha MOC, Teixeira MM, Ribeiro AL, , 2007. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther 5: 727743.[Crossref] [Google Scholar]
  6. Ribeiro AL, Nunes MP, Teixeira MM, Rocha MOC, , 2012. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol 9: 576589.[Crossref] [Google Scholar]
  7. Martins-Melo FR, Ramos Junior AN, Alencar CH, Heukelbach J, , 2012. Multiple causes of death related to Chagas' disease in Brazil, 1999 to 2007. Rev Soc Bras Med Trop 45: 591596.[Crossref] [Google Scholar]
  8. Croft SL, Barrett MP, Urbina JA, , 2005. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 21: 508512.[Crossref] [Google Scholar]
  9. Cancado JR, , 2002. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44: 2937.[Crossref] [Google Scholar]
  10. Villar JC, Perez JG, Cortes OL, Riarte A, Pepper M, Marin-Neto JA, Guyatt GH, , 2014. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 5: CD003463. [Google Scholar]
  11. Fabbro De Suasnábar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, Amicone N, , 2000. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 42: 99109.[Crossref] [Google Scholar]
  12. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F, , 2010. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Nephrol Dial Transplant 51: e69e75. [Google Scholar]
  13. Valencia CN, Mancilla M, Ramos D, Zulantay I, Molina M, Torres A, Corral G, Apt W, , 2012. Tratamiento de la enfermedad de Chagas crónica en Chile. Efectos adversos de nifurtimox. Rev Ibero Latinoam Parasitol 71: 97108. Available at: http://www.socepa.es/revista/IMG/pdf/a12-2.pdf. Accessed February 25, 2014. [Google Scholar]
  14. Levi GC, Lobo IM, Kallás EG, Amato Neto V, , 1996. Etiological drug treatment of human infection by Trypanosoma cruzi . Rev Inst Med Trop Sao Paulo 38: 3538.[Crossref] [Google Scholar]
  15. Pérez-Molina JA, Sojo-Dorado J, Norman F, Monge-Maillo B, Díaz-Menéndez M, Albajar-Viñas P, López-Vélez R, , 2013. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment. Acta Trop 127: 101104.[Crossref] [Google Scholar]
  16. Streiger ML, del Barco ML, Fabbro DL, Arias ED, Amicone NA, , 2004. Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina. Rev Soc Bras Med Trop 37: 365375.[Crossref] [Google Scholar]
  17. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA, , 2007. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe City (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40: 110.[Crossref] [Google Scholar]
  18. Altcheh J, Biancardi M, Lapeña A, Ballering G, Freilij H, , 2005. Congenital Chagas disease: experience in the Hospital de Niños, Ricardo Gutiérrez, Buenos Aires, Argentina. Rev Soc Bras Med Trop 38 (Suppl 2): 4145. [Google Scholar]
  19. Bianchi F, Cucunuba Z, Guhl F, Gonzalez NL, Freilij H, Nicholls RS, Ramirez JD, Montilla M, Florez AC, Rosas F, Saavedra V, Silva N, , 2015. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia. PLoS Negl Trop Dis 10: e0003465.[Crossref] [Google Scholar]
  20. Ministerio de la Protección Social, 2010. Guía para la atención clínica integral del paciente con enfermedad de Chagas. Bogotá, República de Colombia: Ministerio de la Protección Social. Available at: http://www.minsalud.gov.co/Documentos%20y%20Publicaciones/Guia%20de%20atencion%20clinica%20de%20chagas%202010.pdf. Accessed February 25, 2014. [Google Scholar]
  21. Jackson Y, Chatelain E, Mauris A, Holst M, Miao Q, Chappuis F, Ndao M, , 2013. Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment. BMC Infect Dis 13: 85.[Crossref] [Google Scholar]
  22. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Jr Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC, , 2007. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298: 21712181.[Crossref] [Google Scholar]
  23. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ, , 1981. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239245.[Crossref] [Google Scholar]
  24. Coelho HL, Arrais PS, Gomes AP, , 1999. Ceara State Pharmacovigilance System: a year of experience. Cad Saude Publica 15: 631640.[Crossref] [Google Scholar]
  25. Landis JR, Koch GG, , 1977. The measurement of observer agreement for categorical data. Biometrics 33: 159174.[Crossref] [Google Scholar]
  26. Wei LJ, , 1992. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med 11: 18711879.[Crossref] [Google Scholar]
  27. Kleinbaum DG, Klein M, , 2005. Survival Analysis—A Self-Learning Text. New York, NY: Springer. [Google Scholar]
  28. Balakrishnan N, Peng Y, , 2006. Generalized gamma frailty model. Stat Med 25: 27972816.[Crossref] [Google Scholar]
  29. Kim SM, Park J, Kim SH, Park SY, Kim JY, Sung JJ, Park KS, Lee KW, , 2013. Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. PLoS One 8: e82325.[Crossref] [Google Scholar]
  30. Cox C, Chu H, Schneider MF, Munoz A, , 2007. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Stat Med 26: 43524374.[Crossref] [Google Scholar]
  31. R Development Core Team, 2008. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. ISBN 3-900051-07-0. Available at: http://www.r-project.org./. [Google Scholar]
  32. Coura JR, de Abreu LL, Willcox HP, Petana W, , 1997. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation. Rev Soc Bras Med Trop 30: 139144.[Crossref] [Google Scholar]
  33. Gallerano RH, Sosa RR, , 2001. Resultados de estúdio a largo plazo com drogas antiparasitárias em infectados chagásicos crônicos. Rev Fed Arg Cardiol 30: 289296. Available at: http://www.fac.org.ar/revista/01v30n2/galle/galle.PDF. Accessed February 25, 2014. [Google Scholar]
  34. Hasslocher-Moreno AM, do Brasil PE, de Sousa AS, Xavier SS, Chambela MC, Sperandio da Silva GM, , 2012. Safety of benznidazole use in the treatment of chronic Chagas' disease. J Antimicrob Chemother 67: 12611266.[Crossref] [Google Scholar]
  35. Kaur S, Kapoor V, Mahajan R, Lal M, Gupta S, , 2010. Patterns of ADRs and risk factors involved: study in cardiology unit of an Indian tertiary care center. Internet J Pharmacol 8. Available at: http://ispub.com/IJPHARM/8/1/11624. Accessed February 25, 2014. [Google Scholar]
  36. Hughes SG, , 1998. Prescribing for the elderly patient: why do we need to exercise caution? Br J Clin Pharmacol 46: 531533.[Crossref] [Google Scholar]
  37. Sperandio da Silva GM, Mediano MFF, Alvarenga Americano do Brasil PE, da Costa Chambela M, da Silva JA, de Sousa AS, Xavier SS, Rodrigues da Costa A, Magalhães Saraiva R, Hasslocher-Moreno AM, , 2014. A clinical adverse drug reaction prediction model for patients with Chagas disease treated with benznidazole. Antimicrob Agents Chemother 58: 63716377.[Crossref] [Google Scholar]
  38. Agbabiaka TB, Savovic J, Ernst E, , 2008. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 31: 2137.[Crossref] [Google Scholar]
  39. Pinazo MJ, Munoz J, Posada E, Lopez-Chejade P, Gallego M, Ayala E, del Cacho E, Soy D, Gascon J, , 2010. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 54: 48964899.[Crossref] [Google Scholar]
  40. Manne J, Snively CS, Levy MZ, Reich MR, , 2012. Supply chain problems for Chagas disease treatment. Lancet Infect Dis 12: 173175.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 31 Mar 2015
  • Accepted : 27 Jul 2015
  • Published online : 09 Dec 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error